Jaguar Health, Inc. (JAGX) Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Jaguar Health, Inc. NASDAQ:JAGX Healthcare · Biotechnology
Mkt Cap $5.07M
EV -
Net Cash/Sh -
CLOSED · Nov 17 -1.68%$0.3799 CLOSED · Nov 17 Prev close $0.3864 -1.68%Close $0.3799 -2.50%AH close $0.3704 VOL 542K $ Vol $196K RVOL 0.63x
Mkt Cap $5.07M
EV -
VOL 542K sh
$ Vol $196K
RVOL 0.63×
Net Cash/Sh -
Press Release
Jaguar Health Reports Third Quarter 2026 Financials
Jaguar Health reported Q3 2026 total net revenue of $2.3 million, down 24% year-over-year, with prescription product revenue falling 81.9% to $0.55 million after licensing U.S. commercialization of Mytesi and Canalevia-CA1 to Future Pak. Net loss narrowed 39.6% to $5.8 million from $9.6 million a year ago, and non-GAAP recurring EBITDA loss improved to $5.0 million from $9.0 million, driven by roughly $2.0 million in operating expense reductions including dissolution of the salesforce.
• 1d ago AI analysis › Press Release
Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates
Jaguar Health announced it will hold an investor webcast on Tuesday, November 17, 2026 at 8:30 a.m. Eastern to review third-quarter 2026 financials and provide corporate updates. The company expects to file its Form 10-Q for the quarter ended September 30, 2026 on November 16, 2026.
• 4d ago AI analysis › Press Release
Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Jaguar Health stockholders approved all six proposals submitted at the November 6, 2026 Special Meeting of Stockholders. The release provides no details on the proposals themselves, referring investors to the proxy statement filed with the SEC on October 8, 2026.
• 11d ago AI analysis › Press Release
CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Jaguar Health's subsidiary Napo Pharmaceuticals recapped a panel at the 2nd Best of Elite Ped-GI meeting in Dubai, where its CSO and clinical investigators discussed pediatric intestinal failure and crofelemer. Panelists reviewed data from pediatric MVID and SBS-IF patients on liquid oral crofelemer for over a year, showing reduced parenteral support normalized to body weight and improved weight and stature growth parameters.
• 15d ago AI analysis › Press Release
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Jaguar Health's subsidiary Napo Pharmaceuticals reports that liquid oral crofelemer reduced daily parenteral support needs by roughly 15% in an infant with congenital sodium diarrhea due to a GUCY2C mutation, the third rare intestinal-failure indication being evaluated under expanded access. In longer-dosed pediatric patients, weekly PS requirements normalized to body weight fell up to 48% in an MVID patient and up to 40% in two SBS-IF patients after more than 12 months of high-dose therapy, with no significant clinical or laboratory abnormalities.
• 27d ago AI analysis › Press Release
Jaguar Health Provides Update Regarding Special Stock Dividend
Jaguar Health announced that Nasdaq set the ex-dividend date of October 16, 2026 for its previously announced Special Stock Dividend of Series R Convertible Preferred Stock. Shares will trade with due bills from the October 13 record date until the ex-dividend date, meaning sellers during that period give up their right to the dividend.
• 1mo ago AI analysis › Press Release
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Jaguar Health's subsidiary Napo Pharmaceuticals presented positive preliminary open-label pilot data for crofelemer in adult Type 1 short bowel syndrome patients with intestinal failure at ACG 2026 on October 13. Four of six planned subjects completed the 12-week protocol: two saw ostomy volume fall ~5%, one reduced parenteral support volume by 9%, and three improved urinary output by an average of 88%, sustained four weeks after stopping therapy, with no significant adverse events.
• 1mo ago AI analysis › Press Release
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
Jaguar Health reminded stockholders that October 13, 2026 is the record date for its previously declared Special Stock Dividend of Series R Convertible Preferred Stock to holders of common stock and certain warrants. The payment date is October 15, 2026, and each preferred share converts into five common shares on November 2, 2026. CEO Lisa Conte framed the dividend as rewarding stockholders and providing protection against potential dilution while the company evaluates strategic alternatives.
• 1mo ago AI analysis › Press Release
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Jaguar Health announced that subsidiary Napo Pharmaceuticals is sponsoring a panel discussion on intestinal failure at the 2nd Best of Elite Ped-GI meeting in Abu Dhabi on October 30, 2026. Panel participants include Dr. Mohamad Miqdady and Dr. Christos Tzivinikos, both involved in clinical evaluations of crofelemer powder for oral solution in pediatric intestinal failure patients, alongside Jaguar Chief Scientific Officer Pravin Chaturvedi.
• 1mo ago AI analysis › Press Release
Jaguar Health Announces a Special Stock Dividend
Jaguar Health declared a special stock dividend of Series R Convertible Preferred Stock to holders of common stock and certain warrants as of the October 13, 2026 record date, payable October 15. Each preferred share converts into five common shares on November 2, 2026; management framed the dividend as a reward for stockholders and protection against potential dilution while the company evaluates strategic alternatives.
• 1mo ago AI analysis › Press Release
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Jaguar Health's family company Napo Pharmaceuticals announced acceptance of an abstract with preliminary open-label crofelemer data in adult short bowel syndrome with intestinal failure (SBS-IF) for presentation at ACG 2026, held October 9-14 in Nashville. A separate multicenter, randomized double-blind placebo-controlled Phase 2 trial in adult Type 1 SBS patients without colon-in-continuity is ongoing, with results expected early in the second half of 2027. Prior data in pediatric intestinal failure patients showed substantial reductions in weekly parenteral support needs with no significant clinical or laboratory abnormalities.
• 1mo ago AI analysis › Press Release
Jaguar Health Receives Fee Waivers from FDA
The FDA granted Jaguar Health's family company Napo Pharmaceuticals a waiver of the PDUFA fee for Mytesi (crofelemer) for fiscal year 2027. Jaguar also received a fee waiver from FDA's Center for Veterinary Medicine for Canalevia-CA1, its conditionally approved drug for chemotherapy-induced diarrhea in dogs, for fiscal 2027. Both products are commercialized in the U.S.
• 1mo ago AI analysis › Press Release ● Major
Jaguar Health, Inc. Announces Reverse Stock Split
Jaguar Health will effect a 1-for-15 reverse stock split of its common stock effective Thursday, September 17, 2026, with shares trading on a split-adjusted basis at market open under the unchanged JAGX symbol on the Nasdaq Capital Market. The stated purpose is to support the Company's compliance with Nasdaq's listing standards, and the split was approved by stockholders at the April 2026 Special Meeting per the proxy filed with the SEC on March 24, 2026 — the framing signals an active listing-compliance problem rather than a cosmetic share-price move.
• 2mo ago AI analysis › Press Release
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
All randomized pediatric MVID patients in Jaguar Health family company Napo Pharmaceuticals' pivotal crossover trial have entered the single-blind extension phase, receiving blinded doses of crofelemer powder for oral solution as adjunctive therapy to parenteral support. An independent Data Monitoring Committee evaluated safety and tolerability from the randomized double-blind crossover period and authorized continuation of active crofelemer treatment, keeping the study on track to support an NDA filing for microvillus inclusion disease in mid-2027.
• 2mo ago AI analysis › Press Release
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Jaguar Health announced that Neonorm Dog, a plant-based, non-prescription product for digestive support in dogs, is now available on Amazon. The launch extends Jaguar's existing Neonorm franchise, which previously included formulations for foals and calves.
• 2mo ago AI analysis › Press Release
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Jaguar Health's family company Napo Pharmaceuticals is providing crofelemer powder for oral solution on a compassionate use basis to an additional infant with intestinal failure caused by congenital sodium diarrhea, a condition driven by a GUCY2C gene mutation. Data from ongoing investigational studies show weekly parenteral support requirements normalized to body weight fell by up to 48% in one MVID patient and up to 40% in two pediatric SBS-IF patients after more than 12 months of liquid oral crofelemer, with no significant clinical or laboratory abnormalities.
• 2mo ago AI analysis › Press Release
Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Jaguar Health initiated the commercial launch of Neonorm Dog, a plant-based, non-prescription product designed to support normal stool consistency and GI fluid balance in dogs. The launch extends the Neonorm franchise beyond production animals like foals and calves into the companion animal market, with availability expected soon on Amazon and Chewy.
• 2mo ago AI analysis › Press Release
Jaguar Health Reports Second Quarter 2026 Financials
Jaguar Health reported Q2 2026 revenue of $1.2 million, down 59% year-over-year, following the transfer of U.S. commercial rights for Mytesi and Canalevia-CA1 to partner Future Pak. Despite the revenue decline, net losses widened to $12.7 million, though operating losses improved slightly due to reduced commercial expenses.
• 2mo ago AI analysis › Press Release
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
Jaguar Health announced it will hold an investor webcast on August 19, 2026, to review Q2 2026 financial results and provide corporate updates. The company plans to file its Form 10-Q for the quarter ended June 30, 2026, on the same day as the webcast.
• 2mo ago AI analysis › Press Release
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
Jaguar Health announced it has satisfied conditions to receive a $2 million non-dilutive holdback payment from partner Future Pak, bringing total payments under the license agreement to $21 million. The agreement grants Future Pak exclusive marketing rights to Mytesi and Canalevia-CA1 in the U.S., with up to $17 million in additional milestones remaining.
• 3mo ago AI analysis › Press Release
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Jaguar Health announced positive findings from exploratory surveys supporting the commercial opportunity for Neonorm Dog, a plant-based product designed to support digestive health in dogs. The survey of 33 veterinary oncologists indicated that nearly 90% found the concept clinically relevant, while a survey of 18 dog owners showed 94% willingness to purchase the product.
• 3mo ago AI analysis › Press Release
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar Health announced that its subsidiary Napo Pharmaceuticals is providing crofelemer to an infant in the EU for compassionate use to treat intestinal failure caused by microvillus inclusion disease (MVID). Data recently presented at the ESPGHAN 2026 meeting showed that treatment with oral crofelemer for over 12 months reduced parenteral support requirements by up to 48% in MVID patients and 40% in short bowel syndrome patients, with no significant safety issues.
• 3mo ago AI analysis › Press Release
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Jaguar Health presented data at ESPGHAN 2026 demonstrating that its drug crofelemer significantly reduced parenteral support requirements in pediatric intestinal failure patients. Results showed a reduction of up to 48% in normalized weekly parenteral support for one MVID patient and up to 40% for two SBS patients after more than 12 months of therapy.
• 4mo ago AI analysis › Press Release
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Aspire Biopharma Holdings was listed as a presenting company at the recent Life Sciences Virtual Investor Forum hosted by Virtual Investor Conferences. The company's presentation materials are now available for on-demand viewing and will remain accessible for 90 days.
• 4mo ago AI analysis › Press Release
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Jaguar Health announced the mandatory conversion of its Series O Convertible Preferred Stock into common stock at a ratio of 3.209 to 1, effective June 25, 2026. The preferred stock was originally issued as a one-time special dividend in February to reward shareholders and protect against dilution during debt restructuring efforts. The company reiterated its focus on the global development program for crofelemer, a treatment for rare intestinal failure diseases. Management noted that the program continues to generate clinical proof-of-concept data and is part of ongoing business development discussions aimed at securing non-dilutive funding.
• 4mo ago AI analysis › Press Release
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health submitted a New Animal Drug Application (NADA) to the FDA for full approval of crofelemer (Canalevia-CA1) to treat chemotherapy-induced diarrhea (CID) in dogs. The submission is supported by a pivotal effectiveness study where 77% of owners reported effectiveness and 40% saw complete resolution of symptoms, compared to 10.5% in untreated cases.
• 4mo ago AI analysis › Press Release
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Aspire Biopharma Holdings (ASBP) is scheduled to present at the upcoming Life Sciences Virtual Investor Forum on June 25, 2026, at 2:00 PM ET. The event is hosted by Virtual Investor Conferences and features a roster of life sciences companies, allowing investors to view presentations and schedule one-on-one meetings with management teams.
• 4mo ago AI analysis › Press Release
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Jaguar Health's board has initiated a process to explore strategic alternatives, including potential mergers or acquisitions, to maximize stockholder value in alignment with its anticipated NDA filing for crofelemer. Third-party market research estimates the market for the rare intestinal failure indication at $1.1 billion in 2026, growing to $1.5 billion by 2033.
• 4mo ago AI analysis › Press Release
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health
Magdalena Biosciences, a joint venture between Filament Health and Jaguar Health, reported positive preclinical data showing a coca leaf extract prevented weight gain in mice without reducing food intake. The extract is being developed as a prescription drug for post-GLP-1 weight management under the FDA's Botanical Guidance, targeting the significant unmet need of weight regain after cessation of GLP-1 therapies.
• 4mo ago AI analysis › Press Release
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Jaguar Health announced that its joint venture, Magdalena Biosciences, reported positive preclinical results showing a coca leaf extract prevented weight gain in mice on a high-fat diet without reducing food intake. The extract is intended for post-GLP-1 weight loss management under FDA Botanical Guidance, addressing the unmet need of weight regain after stopping appetite-suppressing drugs.
• 4mo ago AI analysis › Press Release
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Jaguar Health announced that CEO Lisa Conte will present at the Life Sciences Virtual Investor Forum on June 24, 2026. The company also reminded investors of two upcoming scientific presentations on crofelemer for pediatric intestinal failure at the ESPGHAN Annual Meeting later that week.
• 5mo ago AI analysis › Press Release
Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
Citizens, Inc. (NYSE: CIA) is scheduled to present at the 93rd Emerging Growth Conference on June 10, 2026. The presentation will feature CEO Jon Stenberg and CFO Jeff Conklin as keynote speakers during the 11:25 – 11:55 time slot.
• 5mo ago AI analysis › Press Release
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Jaguar Health announced that stockholders approved all five proposals at its 2026 Annual Meeting of Stockholders. The meeting was initially held on May 22 and adjourned until June 8 to finalize the voting results.
• 5mo ago AI analysis › Press Release
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health is advancing its FDA-approved drug crofelemer as a novel oral therapy for rare intestinal failure disorders, specifically microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The company highlighted proof-of-concept results showing a liquid formulation of crofelemer reduced the need for parenteral support (TPN/IV fluids) by up to 37% in MVID patients and up to 15% in SBS-IF patients.
• 5mo ago AI analysis › Press Release
Jaguar Health Compliant with Nasdaq Bid Price Rule
Jaguar Health received formal notice from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, removing the threat of delisting. CEO Lisa Conte highlighted that Q1 2026 net revenue surged 816% year-over-year and 527% quarter-over-quarter, driven by a US out-license agreement with Future Pak for Mytesi and Canalevia-CA1.
• 5mo ago AI analysis › Press Release ● Major
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health reported Q1 2026 total net revenue of $20.3 million, an 816% increase year-over-year, driven primarily by a $19.1 million license and grant revenue stream from a new U.S. licensing agreement with Future Pak. The company turned an operating loss of $9.4 million in Q1 2025 into operating income of $10.2 million in Q1 2026, aided by the license revenue and a significant reduction in sales and marketing expenses following the dissolution of its previous sales group. Despite the operational turnaround, Jaguar reported a net loss of $7.0 million for the quarter, with Non-GAAP Recurring EBITDA improving to a loss of $5.1 million from $9.7 million a year earlier.
• 5mo ago AI analysis › Press Release
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Jaguar Health announced it will hold an investor webcast on May 26, 2026, to review Q1 2026 financial results and provide corporate updates. CEO Lisa Conte is scheduled to present virtually at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
• 5mo ago AI analysis › Press Release ● Major
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
accessnewswire.com • 5mo ago Press Release
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
accessnewswire.com • 6mo ago Press Release
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Jaguar Health announced preliminary discussions with the FDA to evaluate a Breakthrough Therapy Designation for crofelemer to treat pediatric Microvillus Inclusion Disease. The filing is supported by data from two patients showing meaningful reductions in weekly parenteral support needs, with a pivotal randomized trial having completed enrollment.
• 6mo ago AI analysis › Press Release
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Jaguar Health announced the planned launch of Neonorm Dog, extending its Neonorm product franchise to support digestive health in dogs. The plant-based, non-prescription product uses a standardized botanical extract derived from the Croton lechleri tree, consistent with the company's existing Foal and Calf lines.
• 6mo ago AI analysis › Press Release ● Major
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
accessnewswire.com • 6mo ago Press Release ● Major
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Jaguar Health received an extension from the Nasdaq Hearings Panel until May 15, 2026, to regain compliance with the $1.00 minimum bid price requirement. To ensure the stock meets this threshold, the company will effect a 1-for-35 reverse stock split effective April 30, 2026, with shares trading on a split-adjusted basis at the market open.
• 6mo ago AI analysis › Press Release ● Major
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
accessnewswire.com • 6mo ago Press Release
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
accessnewswire.com • 6mo ago Press Release ● Major
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
accessnewswire.com • 7mo ago Press Release
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
accessnewswire.com • 7mo ago Press Release ● Major
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
accessnewswire.com • 7mo ago Press Release ● Critical
Jaguar Health Reports 2025 Financials
accessnewswire.com • 7mo ago Press Release
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
accessnewswire.com • 7mo ago Press Release ● Major
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
accessnewswire.com • 8mo ago Press Release
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
accessnewswire.com • 8mo ago Press Release
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
accessnewswire.com • 8mo ago Press Release
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
accessnewswire.com • 8mo ago Press Release
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
accessnewswire.com • 8mo ago Press Release ● Major
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
accessnewswire.com • 8mo ago Press Release ● Major
Jaguar Health Announces a Special One-time Stock Dividend
accessnewswire.com • 8mo ago